AdjuTec Pharma AS

The G7 Commits to Support Development and Company Revenue of new Antibiotics

Oslo, Norway, December 15th, 2021 – AdjuTec Pharma, the antibiotic resistance breaker Company, is pleased to see that the importance and urgency of developing new antibiotic products has been recognized by the leaders of international politics.

G7 Finance Ministers have today (13 December 2021) agreed a G7 statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance.

In a statement from the last G7 meeting all members recognise AMR as requiring a multi-year and multi-stakeholder effort. All G7 members have committed to expedite the implementation of their existing AMR Action Plans and related strategies, and to take additional specific and appropriate steps to address antibiotic market failure and create the right economic conditions to preserve essential existing antibiotics and ensure their access, strengthen AMR antibiotic research and development, and bring new drugs to market where they meet identified public health needs. 

Additionally, AMR-related legislation known as the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act was introduced in the U.S. Congress. This Act aims to address shortcomings in the antibiotic development market and increase public health preparedness by keeping novel antibiotics on the market and improving appropriate use across the health care system.

While current contracts between the government and drug makers base payment on volume, the PASTEUR Act would establish a subscription-style model which would offer antibiotic developers an upfront payment in exchange for access to their antibiotics, encouraging innovation and ensuring the U.S. health care system is prepared to treat antibiotic resistant infections. In the event that the proposed Act is not enacted into law, US Department of Health and Human Services (HHS) has begun the process required to establish a novel payment mechanism with the HHS FY23 proposed legislative program.

G7 Finance Ministers’ Statement on Actions to Support Antibiotic Development - G7 UK Presidency 2021

Nicolaj Weiergang, AdjuTec Pharma Chair of Board, comments: “Of particular importance is the introduction of new Pull incentives in the market. Making revenue from new antibiotic products have been difficult as new products risk limited use to avoid development of resistance. New incentives, including the Pasteur Act in the US will be a game changer securing companies revenue, independent on volume of sale. Similar programs are being introduced in the UK and discussed in EU.”

About antimicrobial resistance (AMR) –

AMR is a global health and development threat. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials are the main drivers in the development of drug-resistant pathogens. Lack of clean water and sanitation and inadequate infection prevention and control promotes the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. In addition, there is a need for more expensive medicines and financial challenges for those impacted. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacteria metallo-ß-lactamase (MBL) enzymes. The technology is developed by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Oslo Cancer Cluster Innovation Park next to the Radium Hospital, Oslo.

For more information, please visit
Please contact: